explore -WSS

explore

author：leisure time 2025-09-03 09:24:35 - browse：5

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： FDA approves first new drug developed for postpartum depression

Wikipedia

WSS

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Community Health Systems hospitals under DOJ investigation

Biden administration plans revamp of organ transplant system

PBM reform efforts get punted in Congress

In utero gene editing: an explainer

Can medical device makers keep up in the race to treat obesity?

knowledge

explore

hotspot

Walensky prepares to leave CDC — and Congress — behind

STAT readers on older presidents, polypills, Medicare, and more

Moonlake's readout produced a cash windfall. Risks remain

In utero gene editing: an explainer

Medicare details structure of new drug price negotiation program

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

How to save PrEP access — and even expand it

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Jerome Adams on the need for new antivirals for Covid

He's a Nobel laureate. Critics say he was misleading on Covid

explore

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Xenotransplantation trials will require adjusting expectations, experts say

The thinking behind the controversial eating disorder chatbot Tessa

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Wikipedia

knowledge

explore

hotspot